Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Company News
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Events
Directory
Editorial team
Search
Close search
Subscribe
Login
Password
Password
Remember me
Forgot password?
Close login form
Market Reports
Excipients step into the spotlight with sustainable and nano solutions
How multifunctional and natural materials are reshaping formulation science
How onco-HPAPI manufacturing is adapting to a new era
The oncology landscape is undergoing a quiet but powerful shift. Pharmaceutical companies, once focused primarily on novel compounds, are now increasingly exploring repurposing opportunities with existing high-potency oncology APIs (onco-HPAPIs)
Outsourcing in pharma: a comprehensive guide to strategic advantages and considerations
Outsourcing in pharma drives agility, compliance, and efficiency—NSF delivers expert audits, training, remediation, and embedded support
Poolbeg granted FDA Orphan Drug Designation for POLB 001
The US FDA grants orphan status to support the development of medicines for rare disorders affecting fewer than 200,000 people in the US
From data silos to streamlined connectivity: how biopharma can prepare for ESMP
Sponsors that centralise their product information will not only help to pre-empt drug shortages but also improve their capacity for collaboration with connected systems and data
Freeze drying ADCs: points to consider for industrial applications
As antibody-drug conjugates gain momentum in the pharmaceutical industry, manufacturers are increasingly looking to implement safe and effective process trains to produce them. Lyophilisation experts at GEA Pharma & Healthcare assess some of the most critical challenges and how to overcome them
The ABCs of ADCs: manufacturing ultra-high potent active ingredients
Senior Technical Manager at Sterling Pharma Solutions, Matt Miklas, presents a pragmatic approach to the safe and cost-effective production of highly potent pharmaceutical molecules, including antibody-drug conjugate (ADC) payloads
Why potency assays are a crucial consideration for CGT manufacturers
Potency assays can enhance the efficiency of cell and gene therapy development and commercialisation, while also bringing down costs
How iPSCs can bridge the translational gap in neuroscience
Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
Clinical trials: current insights and future perspectives
To keep up with the ever-evolving landscape of clinical trials, companies must conform to regulations and consider how to make the study process patient-centric
Recombinant versus synthetic peptide synthesis: the perks and drawbacks
Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
ACHEMA 2024 champions a competitive pharmaceutical industry
More than 2800 exhibitors from 56 nations — as well as 106,001 attendees from 141 countries — gathered in Frankfurt for ACHEMA 2024 to showcase the latest equipment and processes for the pharmaceutical industry
How predictive and preventive maintenance can optimise your pharmaceutical manufacturing line
With a tailored approach to maintenance, manufacturers can extend their system’s lifetime and anticipate time-consuming breakdowns before they happen
Factors driving the expansion of the multiple myeloma drug market
The multiple myeloma market has seen a range of immune-targeting therapeutics gain accelerated approval from the US FDA … and sales are predicted to skyrocket in the coming years
Biosecurity threats and business as usual
A new version of a United States congressional bill (the Biosecure Act) that restricts US companies from doing business with certain Chinese biotechnology organisations, including WuXi AppTec and WuXi Biologics, gives American companies until 2032 to terminate their associations with these firms and find new partners
Annex 1-compliant freeze drying: a technology supplier’s perspective
Jessica Wagner, Validation Engineer at GEA, tells Dr Kevin Robinson how the company has embraced the updated version of Annex 1 and implemented the new changes. Key objectives were to remain compliant and demonstrate to their customers — both current and future — how the amends would be incorporated into ongoing or upcoming projects
Previous
1
2
(current)
3
4
5
6
7
…
15
Next
Trending Articles
You need to be a subscriber to read this article.
Click here
to find out more.
From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages
An EU-level stockpile may work, but only if it’s flexible, closely monitored and built with logistics in mind. Industry players say drug security will depend less on volume and more on data, digital oversight and early collaboration throughout the supply chain
A grandmaster’s approach to successful tableting
Tableting is a fundamental unit operation in the production of pharmaceutical oral solid dosage forms. Despite its long history of use and the development of innovations such as extended dwell times, unique technologies that independently and simultaneously measure and control both tablet weight and hardness, and a weight control system that provides increased sensitivity at lower forces, production problems still occur. Here, Dr Harald Stahl, Group Director, Application and Strategy Management, GEA, provides some troubleshooting tips from an unlikely source: the chess board
The modularisation of chemical API synthesis
The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers
Leaders of transformation
Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development
Is the production of biologic drugs ready for an overhaul?
Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson
Upcoming event
CPhI Milan
6–8 October 2026 | Exhibition | Fiera Milano, Italy
See all
